Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $28,224.00 in Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 8,064 shares of the business’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $3.50, for a total value of $28,224.00. Following the transaction, the insider now owns 1,255,730 shares in the company, valued at $4,395,055. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Price Performance

Shares of GNLX stock opened at $3.32 on Friday. The stock’s 50-day simple moving average is $5.76 and its 200-day simple moving average is $10.90. Genelux Co. has a fifty-two week low of $3.07 and a fifty-two week high of $40.98.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). As a group, equities analysts predict that Genelux Co. will post -0.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on GNLX. Benchmark restated a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a research note on Wednesday, April 3rd. HC Wainwright cut their price objective on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd.

Hedge Funds Weigh In On Genelux

Hedge funds have recently bought and sold shares of the business. Amalgamated Bank lifted its position in shares of Genelux by 250.8% in the third quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock valued at $26,000 after acquiring an additional 770 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Genelux by 216.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock worth $41,000 after buying an additional 2,021 shares in the last quarter. Barclays PLC increased its stake in Genelux by 516.4% during the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock worth $83,000 after acquiring an additional 2,835 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Genelux by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock worth $87,000 after acquiring an additional 1,573 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in Genelux by 17.6% during the fourth quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock worth $91,000 after acquiring an additional 966 shares during the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.